Holiday Language Blog Series – Part Three, Cultural Adaptation

Welcome to the third and final installment of our three-part blog series highlighting the importance of choosing the right language services partner.

Cultural Adaptation and Localization

Cultural adaptation and localization of clinical trial translations can be pivotal components to the success of a clinical trial. Localization and cultural adaptation go beyond textual translation and modify content for regional and/or local consumption. Localization modifies content and elements of a trial to appeal to patient’s cultural preferences in their own local language.

Cultural adaptation and localization services are just as important as translation services to accurately represent the implementation and outcomes of a clinical trial. Cultural adaptation can improve the quality of formally translated instruments by ensuring tasks, stimuli, instructions and, scoring are appropriate for populations of interest. Detailed attention to these issues is likely to enhance any real signal in a clinical trial, where the translated instrument serves as an endpoint.

The notion of Santa Claus is not a uniquely American tradition. In fact, many countries and cultures around the world celebrate the tradition of Santa Claus although symbolism, languages and, customs differ greatly.

 

 

Using VeraSci’s methods for cultural adaptation, errors can be identified and corrected prior to use in clinical trials, yielding gains in the reliability and validity of translated instruments and avoiding costly delays. Our linguistic experts bring not only translation skills and cultural awareness to each project, but clinical trials experience as well, ensuring that the information provided does what it should do: enable trial participant understanding.

Accurate translation, interpretation, and cultural adaptation are vital to a successful global clinical trial. By working together with sponsors, regulatory committees and other suppliers of research-related services, VeraSci can cut costs, help you to meet critical trial deadlines, and ensure successful international clinical trials.

5 Benefits of Using VeraSci for Global Language Services

  • Quality: KPI of 99% first-time accuracy for all translations done by humans. Our unique workflow includes quality assurance oversight by a team of PhD-level scientists as well as in-house software development and information technology teams, ensuring that the complexities of medical and technical terminologies are correctly translated.
  • Clinical Trial Expertise: Our linguists are often specialists in their field and are considered subject matter experts. They must pass a stringent nationally and internationally recognized certification process and are supported by a team of PhDs and clinical professionals to guarantee scientifically accurate translations at all times. VeraSci has extensive experience in executing large multi-year projects around the globe and is dedicated to ensuring the highest level of language services delivered at the pace to support global clinical trials.
  • Customer Satisfaction: At VeraSci, we go beyond the industry standard to provide a higher level of translation accuracy and agility by delivering customer-focused solutions and processes.
  • On-Time Delivery: Our 100% on-time delivery metric illustrates our commitment to meeting deadlines. Guaranteed quicker turnaround times due to in-house linguistic assets and centralized project management operations
  • Competitive Pricing: VeraSci’s long-term relationships with our expert team of linguists allows us to obtain lower cost, giving us the flexibility to meet client requirements and customize project approach to meet budget requirements.

 

Click here to read Holiday Language Blog Series – Part One, Translation

Click here to read Holiday Language Blog Series – Part Two, Interpretation

Development of a Patient-Reported Outcomes Symptom Measure of Patients with Non-Transfusion-Dependent Thalassemia (NTDT-PRO ©)

Ali Taher 1 | Vip Viprakasit 2 | Maria Domenica Cappellini 3 | Pranee Sutcharitchan 4 |Richard Ward 5 | Dalia Mahmoud 6 | Abderrahmane Laadem 6 | Anzalee Khan 7,8 |Chad Gwaltney 9 | Gale Harding 10 | Kenneth Attie 11 | Xiaosha Zhang 11 | Jun Zou 6 | Joseph Pariseau6 | X. Henry Hu 6† | Antonis Kattamis 12

Abstract
β-Thalassemia, a hereditary blood disorder caused by reduced or absent synthesis of the β-globin chain of hemoglobin, is characterized by ineffective erythropoiesis, and can manifest as nontransfusion-dependent thalassemia (NTDT) or transfusion-dependent thalassemia (TDT). Many patients with NTDT develop a wide range of serious complications that affect the survival and quality of life (QoL). Patient-reported outcomes (PRO), including health-related QoL (HRQoL), are important tools for determining patient health impairment and selecting appropriate treatment. However, there are currently no disease-specific PRO tools available to assess symptoms related to chronic anemia experienced by patients with NTDT. This study aimed to develop a new, US Food and Drug Administration (FDA)-compliant PRO of chronic anemia symptoms, the NTDT-PRO© tool, for use in patients with NTDT. Participants had a median age of 36 years (range, 18-47) and 60% were female. The initial development of the NTDT-PRO tool involved concept-elicitation interviews with 25 patients from 3 centers (in Lebanon, Greece, and Canada); subsequent interview discussions and clinical input resulted in the generation of 9 items for inclusion in the draft NTDT-PRO. Following a round of cognitive interviews involving 21 patients from 2 centers (in Lebanon and Greece), 4 items (Pain, Headaches, Ability to Concentrate, and Paleness) were removed from the draft NTDT-PRO. The final NTDT-PRO comprises 6 items that measure Tiredness, Weakness, and Shortness of Breath, with or without Physical Activity. The NTDT-PRO is a new disease-specific HRQoL tool for patients with NTDT, developed using a thorough methodology based on FDA 2009 PRO development guideline.

Follow the link below for the full article:

Taher_et_al-NTDT-PRO Development-2018-American_Journal_of_Hematology

Validation of a Patient-Reported Outcomes Symptom Measure of Patients with Non-Transfusion-Dependent Thalassemia (NTDT-PRO ©)

Ali Taher 1 | Maria Domenica Cappellini 2 | Vip Viprakasit 3 | Pranee Sutcharitchan 4 |Dalia Mahmoud 5 | Abderrahmane Laadem 5 | Anzalee Khan 6,7 | Chad Gwaltney 8 |Gale Harding 9 | Kenneth Attie 10 | Xiaosha Zhang10 | Jun Zou 5 | Joseph Pariseau 5 |X. Henry Hu 5† | Antonis Kattamis 11

Abstract
This study demonstrates the quantitative characteristics of the first patient-reported outcome (PRO) tool developed for patients with nontransfusion dependent β-thalassemia (NTDT), the NTDT-PRO©. A multicenter validation study was performed over 24 weeks, involving 48 patients from Italy, Lebanon, Greece, and Thailand. Most patients were female (68.8%), with a median age
of 34.5 years (range, 18-52); 66.7% were diagnosed with β-thalassemia intermedia, and median time since diagnosis was 22 years (range, 0-43). The NTDT-PRO comprises 6 items across 2 domains (Tiredness/Weakness and Shortness of Breath [SoB]), and was valid and reliable, with good consistency. At baseline, most patients reported symptoms as present via the NTDT-PRO,
and were highly compliant, ≥90% completing the NTDT-PRO tool. In a pairwise correlation analysis, all items were positively correlated. Correlations between NTDT-PRO and existing tools— 36-Item Short Form Health Survey version 2 (SF-36v2) and Functional Assessment of Cancer Therapy-Anemia (FACT-An)—were assessed at weeks 1, 3, and 12; robust correlations were seen between SoB and SF-36v2-Vitality (rs = −0.53), and between SoB and Fact-An-Fatigue Experience (rs = −0.66) at week 1. Internal consistency was high for both Tiredness/Weakness (Cronbach alpha, 0.91) and SoB (Spearman-Brown coefficient, 0.78); intraclass correlation coefficients were high (Tiredness/Weakness, 0.88 and 0.97; SoB, 0.92 and 0.98), demonstrating stability. Further studies are required to fully support the validity of this tool, this study demonstrated the usefulness of the NTDT-PRO in the clinical setting and for longitudinal clinical research, particularly in trials where patient health-related quality of life is expected to change.

Follow the link below for the full article:

Taher_et_al-NTDT-PRO Validation-2018-American_Journal_of_Hematology

Significant Enhancements Announced for Pathway, VeraSci’s Proprietary eCOA Platform

Significant Enhancements Announced for Pathway,

VeraSci’s Proprietary eCOA Platform

Integrating Clinical, Cognitive and Functional Assessments onto one device.

 

Durham, NC—December 6, 2018—VeraSci, a global clinical technology and research services company, announces multiple significant enhancements to Pathway, their proprietary eCOA platform. Pathway, which reinvented how raters, sponsors and site administrators conduct assessments and scales for clinical trials, now offers enhanced data collection and administration, and access to a larger number and type of scales and assessments.

The Pathway team worked with raters, scale-developers, and sponsors to ensure that all Pathway users would derive optimal functionality while accommodating the needs of each study and site. The improved flexibility of Pathway allows for the use of a single device for multiple assessments and multiple protocols, permits high enrolling sites to use different devices for parallel assessment of multiple patients, and easily integrates all of the data. VeraSci’s proprietary assessments, BAC and VRFCAT, and licensed gold standard endpoints and safety measures for multiple therapeutic areas such as the EDSS and C-SSRS, are now accessible through a single Pathway-enabled device. In addition, raters can administer assessments on Pathway and obtain consent from test subjects on the same device.

Available in multiple languages, Pathway is able to accommodate a sponsor’s specific needs for an integrated experience in a variety of countries, with negligible failure rates or device issues. VeraSci’s multi-lingual tech support teams in Europe, Asia, and the United States provide support in sites’ local languages, and VeraSci’s Global Language Solutions team provides scientifically valid translations and cultural adaptations of required assessments.

The feedback from users has been extraordinary. Dave Walling, Ph.D. of CNS Network LLC, explains, “Pathway simplifies the process for raters at the site level by integrating the assessments into one system. Rating on a tablet can often be a frustrating experience as there are multiple log-ins, connection problems, and technological mishaps…Pathway helps to combat those issues and makes the process easier for staff, subjects and ultimately, sponsors”.

If you are interested in learning more about Pathway, an FDA 21 CFR Part 11 Compliant eCOA platform, visit our website; https://verascience.com/what-we-do/our-solutions/pathway/

About VeraSci

Founded in 2004, VeraSci has a worldwide presence in clinical trial development, clinical and cognitive assessment and language services. VeraSci brings deep expertise, strategic innovation and unwavering commitment to every project, allowing each client to deliver data supporting innovative therapies.

###

VeraSci is a registered trademark of NCT Holdings in the United States and/or other countries.

I'm interested in Pathway

  • By sending us your information, you are agreeing to allow VeraSci to retain certain personal information provided by you in order to contact you in the future. If you have any questions about how we handle your data, please refer to our Privacy Policy located at https://www.verascience com/privacy-policy/